Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study;Number of Participants With Each Solicited Systemic AEs up to 7 Days After Study Vaccination;Number of Participants With Medically Attended Adverse Events (MAAEs) From Study Vaccination Through the End of the Study;Number of Participants With Serious Adverse Events (SAEs) From Study Vaccination Through the End of the Study;Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After Study Vaccination;Number of Participants With Unsolicited AEs up to 28 Days After Study Vaccination, Including Clinically Relevant Abnormal Clinical Safety Laboratory Findings

Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study;Number of Participants With Each Solicited Systemic AEs up to 7 Days After Study Vaccination;Number of Participants With Medically Attended Adverse Events (MAAEs) From Study Vaccination Through the End of the Study;Number of Participants With Serious Adverse Events (SAEs) From Study Vaccination Through the End of the Study;Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After Study Vaccination;Number of Participants With Unsolicited AEs up to 28 Days After Study Vaccination, Including Clinically Relevant Abnormal Clinical Safety Laboratory Findings

Percentage of participants with adverse events of special interest (AESIs) from study vaccination through the end of the study;Percentage of participants with each solicited systemic AEs up to 7 days after study vaccination;Percentage of participants with medically attended adverse events (MAAEs) from study vaccination through the end of the study;Percentage of participants with serious adverse events (SAEs) from study vaccination through the end of the study;Percentage of participants with solicited local adverse events (AEs) up to 7 days after study vaccination;Percentage of participants with unsolicited AEs up to 28 days after study vaccination, including clinically relevant abnormal clinical safety laboratory findings

Percentage of participants with adverse events of special interest (AESIs) from study vaccination through the end of the study;Percentage of participants with each solicited systemic AEs up to 7 days after study vaccination;Percentage of participants with medically attended adverse events (MAAEs) from study vaccination through the end of the study;Percentage of participants with serious adverse events (SAEs) from study vaccination through the end of the study;Percentage of participants with solicited local adverse events (AEs) up to 7 days after study vaccination;Percentage of participants with unsolicited AEs up to 28 days after study vaccination, including clinically relevant abnormal clinical safety laboratory findings